Table 1.
Baseline characteristics of the patients
|
Variable
|
All (n = 68)
|
Surgery (n = 49)
|
Exploration (n = 19)
|
P
value
|
| Age (yr) | 54.3 ± 1.4 | 52.6 ± 1.7 | 58.6 ± 2.2 | 0.435 |
| Gender, Male | 50 (73.5%) | 34 (69.4%) | 16 (84.2%) | 0.924 |
| HBV infection | 16 (23.5%) | 13(26.5%) | 3 (15.8%) | 0.997 |
| HCV infection | 4 (5.9%) | 2 (4.1%) | 2 (10.5%) | 0.314 |
| Ascites | 14 (20.6%) | 1 (2.0%) | 13(68.4%) | < 0.001 |
| Tumor size(cm) | 6.9 ± 0.3 | 6.8 ± 0.4 | 7.63 ± 0.5 | 0.495 |
| ALT (IU/L)(median) | 1.8-92.1 (26) | 1.8-92.1 (24.9) | 23-76.3 (32.1) | 0.031 |
| AST (IU/L) (median) | 9.6-74.2 (29) | 9.6-74.2 (27.3) | 18.2-61.9 (31) | 0.142 |
| ALP (U/L) (median) | 13.4-280.5 (82.8) | 13.4-280.5 (81.4) | 45.3-109.9 (85.4) | 0.149 |
| GGT (U/L) (median) | 11-325.6 (42.4) | 11-325.6 (41.1) | 28.9-104.7 (45.8) | 0.512 |
| TBIL (mg/dL) (median) | 4.2-140.0 (18) | 4.2-140 (18.1) | 4.2-42.6 (17.8) | 0.707 |
| CA19-9 (U/mL) (median) | 21-2000 (34.5) | 21-1891 (36) | 22-2000 (30) | 0.104 |
| Differentiation | 0.536 | |||
| Poor | 30 (44.1%) | 20 (40.8%) | 10 (40.052.6 | |
| Poor-moderate | 24 (35.3%) | 19 (38.8%) | 5 (26.3%) | |
| Moderate | 14 (20.6%) | 10 (20.4%) | 4 (21.1%) | |
| Nodal metastasis | 33 (48.5%) | 14 (28.6%) | 19 (100.0%) | < 0.001 |
| Tumor location | < 0.001 | |||
| Left lobe | 28 (41.2%) | 11 (22.4%) | 17 (89.5%) | |
| Right lobe | 40 (58.8%) | 38 (77.6%) | 2 (10.5%) | |
| Vascular invasion | 31 (45.6%) | 13 (26.5%) | 19 (100.0%) | < 0.001 |
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Glutamic pyruvic transaminase; AST: Glutamic oxaloacetic transaminase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyltransferase; TBIL: Total bilirubin; CA19-9: Carbohydrate antigen 19-9.